A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
SY-2101 is being studied as a treatment for participants with a type of leukemia called acute
promyelocytic leukemia (APL). SY-2101 is an oral form of a drug called arsenic trioxide
(ATO). ATO is already used to treat APL in a form that is given as an intravenous (IV)
infusion (through a needle in the arm). SY-2101 is a different form of ATO that is taken
orally (by mouth).
This trial will include participants with low-risk APL in remission, who are receiving
standard of care treatment with all-trans-retinoic acid (ATRA) and intravenous ATO, during
the consolidation phase of chemotherapy with low-risk APL. The participants in this trial
will get continued treatment with ATO and ATRA to help keep their cancer from coming back.
There will be some weeks when participants receive intravenous ATO and others when they
receive SY-2101 (ATO taken orally).